Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Xenetic Biosciences (NASDAQ: XBIO) will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:00 PM EDT, led by CEO Jeffrey Eisenberg. The company focuses on advancing its personalized CAR T platform, XCART™, targeting tumor-specific neoantigens. After the presentation, there will be opportunities for virtual one-on-one investor meetings. A live video webcast will be accessible on the company's website, with a replay available for 90 days.
- None.
- None.
Live video webcast with CEO, Jeffrey Eisenberg, on Wednesday, September 16th at 12:00 PM EDT
FRAMINGHAM, MA / ACCESSWIRE / September 9, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 12:00 PM EDT.
In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website here.
A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company's website (xeneticbio.com). The video webcast replay will be made available two hours following the event and will be archived for 90 days.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.
For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/604851/Xenetic-Biosciences-Inc-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference
FAQ
When is Xenetic Biosciences' presentation at the H.C. Wainwright Conference?
Who is presenting for Xenetic Biosciences at the conference?
What is the focus of Xenetic Biosciences?
Will there be a replay of the Xenetic presentation?
